The total return over the past 12 months is -30.91% vs. +16.94% for the S&P 500. So far it's up -44.57% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (30.91%) | +43.37% | +54.74% | +3.85% | N/A | N/A |
| Total Return CAGR | (30.91%) | +43.37% | +54.74% | +3.85% | N/A | N/A |
| Revenue CAGR | +8.04% | +35.01% | +54.55% | +50.22% | N/A | N/A |
| Net Income CAGR | (19.13%) | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | (17.24%) | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | +77.08% | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | +78.23% | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
ADMA Biologics, Inc. (ADMA)
| Year | Start price | End price | ADMA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $18.24 | $10.11 | (44.57%) | +14.51% | (59.08%) |
| 2025 | $17.15 | $18.24 | +6.36% | +17.72% | (11.36%) |
| 2024 | $4.52 | $17.15 | +279.42% | +24.89% | +254.53% |
| 2023 | $3.88 | $4.52 | +16.49% | +26.19% | (9.70%) |
| 2022 | $1.41 | $3.88 | +175.18% | (18.17%) | +193.35% |
| 2021 | $1.95 | $1.41 | (27.69%) | +28.74% | (56.43%) |
| 2020 | $4.00 | $1.95 | (51.25%) | +18.37% | (69.62%) |
| 2019 | $2.39 | $4.00 | +67.36% | +31.22% | +36.14% |
| 2018 | $3.21 | $2.39 | (25.55%) | (4.56%) | (20.99%) |
| 2017 | $5.12 | $3.21 | (37.30%) | +21.70% | (59.00%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
